Purpose
The aim of this research was to further investigate the contribution of CD20 antigen expression to rituximab activity and define the mechanisms responsible for CD20 downregulation in rituximab-resistant cell lines (RRCL).
Experimental Design
Rituximab-sensitive, rituximab-resistant cell lines, and primary neoplastic B-cells were evaluated by Chromium51-release assays, ImageStream image analysis, immunohistochemical staining, flow cytometric analysis, CD20 knockdown, promoter activity, chromatin immunoprecipitation (ChIP) analysis of CD20 promoter, and CD20 plasmid transfection experiments in order to identify mechanisms associated with CD20 regulation in rituximab-resistant cells.
Results
RRCL exhibited a gradual loss ofCD20 surface expressionwith repeated exposure to rituximab. We identified a CD20 antigen surface threshold level required for effective rituximab-associated complement-mediated cytotoxicity (CMC). However, a direct correlation between CD20 surface expression and rituximab-CMC was observed only in rituximab-sensitive cell lines (RSCL). CD20 promoter activity was decreased in RRCL. Detailed analysis of various CD20 promoter fragments suggested a lack of positive regulatory factors in RRCL. ChIP analysis showed reduced binding of several key positive regulatory proteins on CD20 promoter in RRCL. Interluekin-4(IL-4)induced higher CD20 promoter activityand CD20 expression, but modestly improving rituximab activity in RRCL and in primary B-cell lymphoma cells. Forced CD20 expression restored cytoplasmic but not surface CD20, suggesting the existence of a defect in CD20 protein transport in RRCL.
Conclusion
We identified several mechanisms that alter CD20 expression in RRCL and demonstrated that, while CD20 expression is important for rituximab activity, additional factors likely contribute torituximab sensitivityin B-cell lymphoma.